Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Melanoma 2Advanced Malignancies 2Urothelial Cancer 1Thyroid Neoplasms 1Solid Tumors, KRAS Mutation 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Prostatic Neoplasms 1Prostate Cancer Metastatic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Opioid-Related Disorders 1Lung Neoplasms 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Leiomyosarcoma 1KRAS p.G12C Mutant Advanced Solid Tumors 1Hematologic Neoplasms 1Healthy Adult Participants 1Glioma 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Cancer Pain 1

Interventions

Fulvestrant 125Trastuzumab 114Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Capecitabine 72Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 60trastuzumab deruxtecan 57Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 49Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 40olaparib 39Standard of Care 36Biopsy 33sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Doxorubicin 30Exercise 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × Midazolam × 1 year × Clear all
NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

NCT04557449 2025-10-01

CDK4i

Pfizer

Phase 2 Active not recruiting
362 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT06547164 2025-09-04

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

AstraZeneca

Phase 1 Completed
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡